KDR and hepatocellular carcinoma: In conclusion, although inhibitory activities of compound 6 against Raf kinases and VEGFR2 were weaker than those of sorafenib, the similar degree of in vivo anti-tumour efficacy suggests that compound 6 may be considered as an effective compound targeting HBx-positive HCC while causing a less toxic effect on normal epithelial cells.